A secret shopper study has unveiled the prescribing practices of nearly 50 telehealth sites offering popular GLP-1 medications for weight loss. This investigation highlights the rapid expansion of direct-to-consumer telehealth companies that have emerged in response to increasing patient demand for GLP-1s, such as semaglutide and tirzepatide, particularly in the wake of supply shortages that have led to a rise in unapproved compounded alternatives.
As online prescribing becomes more prevalent, concerns from clinicians and public health experts regarding the adequacy of clinical oversight in virtual care settings have intensified. The study, published in the Journal of the American Medical Association, involved a researcher from Yale University posing as a patient to document the ease of obtaining these prescriptions. The findings underscore a troubling trend: it is alarmingly simple for consumers to secure GLP-1 medications online, raising questions about patient safety and the integrity of telehealth practices.
Start your 7-day trial and see what the database can do →
